Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

<p>HRR gene mutations found in WGS/WES or clinical BRCA1/2 mutational testing.</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Sanna Pikkusaari (15055802) (author)
Rannpháirtithe:	Manuela Tumiati (15011915) (author), Anni Virtanen (15055805) (author), Jaana Oikkonen (14948281) (author), Yilin Li (15055808) (author), Fernando Perez-Villatoro (15055811) (author), Taru Muranen (15055814) (author), Matilda Salko (15055817) (author), Kaisa Huhtinen (15055820) (author), Anna Kanerva (15055823) (author), Heidi Koskela (15055826) (author), Johanna Tapper (15055829) (author), Riitta Koivisto-Korander (15055832) (author), Titta Joutsiniemi (15055835) (author), Ulla-Maija Haltia (15055838) (author), Heini Lassus (15055841) (author), Sampsa Hautaniemi (14948308) (author), Anniina Färkkilä (14948278) (author), Johanna Hynninen (14932815) (author), Sakari Hietanen (14932818) (author), Olli Carpén (14932812) (author), Liisa Kauppi (15055844) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Prognostic biomarkers Chemotherapy DNA Damage and Repair Drug Resistance Clinical drug resistance Gynecological Cancers Ovarian cancer Precision Medicine
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
de réir: Stephanie L. Wethington (16354020)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
de réir: Jiachun Su (16990970)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
de réir: Xiaohong Hong (22681698)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
de réir: Seung Yeon Oh (15051017)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
de réir: Kavya Ramkumar (16474203)
Foilsithe / Cruthaithe: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
de réir: Phyllis S.Y. Chong (17141520)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
de réir: Phyllis S.Y. Chong (17141520)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Movie S1 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
de réir: Jill Gallaher (16799594)
Foilsithe / Cruthaithe: (2025)

Movie S2 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
de réir: Jill Gallaher (16799594)
Foilsithe / Cruthaithe: (2025)

Movie S3 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
de réir: Jill Gallaher (16799594)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pp4vud8t1rqib9a7a3tmq3t21l